Spark Therap Cmn (ONCE) 61.65 $ONCE Spark Thera
Post# of 273254
Posted On: 09/22/2016 3:20:56 PM
Spark Therap Cmn (ONCE) 61.65 $ONCE
Spark Therapeutics to Participate in Multiple Upcoming Conferences
GlobeNewswire - Wed Sep 21, 6:30AM CDT
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing potential one-time, life-altering treatments, announced today that members of company management or key investigators will present at the following upcoming conferences:
ONCE: 61.65 (-1.74)
Covered Call reports for Spark Therapeutics, Potash Corporation of Saskatchewan, GNC Holdings, Weight Watchers and Intersil Corporation include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Sep 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GNC, ISIL, ONCE, POT, and WTW.
ONCE: 61.65 (-1.74), GNC: 20.34 (+0.10), POT: 16.34 (+0.25), ISIL: 21.92 (-0.02), WTW: 10.75 (+0.27)
Spark Therapeutics to Participate in Multiple September Conferences
GlobeNewswire - Wed Aug 31, 6:30AM CDT
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments, announced today that members of company management or key investigators will present at the following major investor and scientific/medical conferences in September:
ONCE: 61.65 (-1.74)
Spark Therapeutics Reports Second Quarter 2016 Financial Results and Recent Business Highlights
GlobeNewswire - Wed Aug 10, 6:30AM CDT
Updated timing of the completed BLA submission for voretigene neparvovec
ONCE: 61.65 (-1.74)
Spark Therapeutics Announces New Positive Data from Continuation of Phase 3 Trial of Voretigene Neparvovec
GlobeNewswire - Wed Aug 10, 6:00AM CDT
Of the nine crossover subjects, eight responders demonstrated the maximum improvement measurable on the primary endpoint at one year
ONCE: 61.65 (-1.74)
Drug Stock Earnings to Watch on Aug 10: ONCE, COLL & ARGS
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 8:24AM CDT
The Q2 earning season is drawing to a close as we now have releases from approximately 433 S&P 500 members, accounting for 87.7% of the index's total market capitalization.
ARGS: 4.97 (-0.19), ONCE: 61.65 (-1.74), COLL: 15.70 (+2.88)
Chipotle Mexican Grill, Mercadolibre Incorporated, Spark Therapeutics, Quanta Services Inc., and Nike and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Mon Aug 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CMG, MELI, NKE, ONCE, and PWR.
PWR: 25.91 (+0.20), NKE: 55.36 (+0.02), ONCE: 61.65 (-1.74), CMG: 409.55 (+9.80), MELI: 190.71 (+3.96)
ONCE Crosses Above Average Analyst Target
ETFChannel.com - Tue Aug 02, 8:04AM CDT
In recent trading, shares of Spark Therapeutics Inc have crossed above the average analyst 12-month target price of $58.75, changing hands for $58.87/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to...
ONCE: 61.65 (-1.74)
Spark Therapeutics, Inc. to Host Conference Call on August 10th at 8:30a.m. to Discuss Second Quarter 2016 Results
GlobeNewswire - Tue Aug 02, 6:30AM CDT
Spark Therapeutics (NASDAQ:ONCE) today announced that it will host a conference call on Wednesday, August 10, 2016 at 8:30 a.m. ET to report corporate and financial results for the three and six months ended June 30, 2016.
ONCE: 61.65 (-1.74)
Spark Therapeutics Announces Closing of Public Offering
GlobeNewswire - Mon Jun 20, 3:01PM CDT
Spark Therapeutics, Inc. ("Spark"
(NASDAQ:ONCE) announced today the closing of its previously announced underwritten public offering of common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission, including the exercise in full by the underwriters of their option to purchase an additional 525,000 shares from Spark at the public offering price of $45.00 per share, less the underwriting discount. The exercise of the option brought the total number of shares sold in the offering to 4,025,000, consisting of 3,025,000 shares sold by Spark and 1,000,000 shares sold by The Children's Hospital of Philadelphia Foundation ("CHOP", and increased the aggregate net proceeds to Spark to approximately $128.0 million, after deducting underwriting discounts and before offering expenses. Spark did not receive any proceeds from the sale of shares by CHOP.
JPM: 67.32 (+0.48), ONCE: 61.65 (-1.74)
Spark Therapeutics Announces Launch of Public Offering
GlobeNewswire - Mon Jun 13, 3:47PM CDT
Spark Therapeutics, Inc. ("Spark" (NASDAQ:ONCE) announced today that it has commenced an underwritten public offering of 3,500,000 shares of its common stock pursuant to an automatically effective shelf registration statement that has been filed with the Securities and Exchange Commission. The offering consists of 2,500,000 shares being offered by Spark and 1,000,000 shares being offered by The Children's Hospital of Philadelphia Foundation ("CHOP". In addition, Spark is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 525,000 shares at the public offering price, less the underwriting discount. Spark will not receive any proceeds from the sale of shares by CHOP. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
JPM: 67.32 (+0.48), ONCE: 61.65 (-1.74)
Spark Therapeutics Announces Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity
GlobeNewswire - Mon Jun 13, 6:15AM CDT
All four subjects received one-time administration of SPK-9001 at initial low dose for a cumulative 58-weeks of follow-up without the need for immunosuppression
ONCE: 61.65 (-1.74), PFE: 34.18 (-0.10)
Spark Therapeutics, Inc. to Host Conference Call on Monday June 13th at 8:30 a.m. to Discuss SPK-9001 Phase 1/2 Data for the Treatment of Hemophilia B Presented at EHA
GlobeNewswire - Thu Jun 09, 6:30AM CDT
Spark Therapeutics (NASDAQ:ONCE) announced today that it will host a conference call on Monday, June 13, 2016 at 8:30 a.m. ET to discuss updated results of the first cohort from the ongoing Phase 1/2 clinical trial of SPK-9001, the lead investigational compound in the SPK-FIX program in collaboration with Pfizer, Inc., which is being studied for the treatment of hemophilia B. Spark also will provide an update on preclinical data in its SPK-FVIII program for the treatment of hemophilia A.
ONCE: 61.65 (-1.74)
Spark Therapeutics Announces Participation and Attendance for Conferences in June
GlobeNewswire - Mon Jun 06, 6:30AM CDT
Spark Therapeutics (NASDAQ:ONCE) announced today that members of its management team will participate in and attend the following conferences in June:
ONCE: 61.65 (-1.74)
Pfizer's (PFE) Trumenba Accepted for Review in the EU
Zacks Equity Research - Zacks Investment Research - Mon May 23, 9:33AM CDT
Pfizer (PFE) and Spark Therapeutics (ONCE) announced encouraging new hemophilia B data; Pfizer also announced that Trumenba is under review in the EU.
ANIP: 66.68 (+1.56), ONCE: 61.65 (-1.74), PFE: 34.18 (-0.10), BMY: 56.45 (+0.52)
Spark Therapeutics and Pfizer Announce Data from Initial Subjects in Hemophilia B Trial Demonstrating Consistent Therapeutic Levels of Factor IX Expression
GlobeNewswire - Thu May 19, 5:30AM CDT
Subjects received one-time administration of a highly optimized gene therapy at initial low dose without the need for immunosuppression
ONCE: 61.65 (-1.74), PFE: 34.18 (-0.10)
Spark Therapeutics Reports First Quarter 2016 Financial Results and Recent Business Highlights
GlobeNewswire - Wed May 04, 6:29AM CDT
Company makes progress across multiple programs
ONCE: 61.65 (-1.74)
Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Pipeline Review 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Biovista, Khondrion, Spark Therapeutics - Research and Markets
BusinessWire - Wed May 04, 2:50AM CDT
Research and Markets has announced the addition of the "Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H1 2016" drug pipelines to their offering.
ONCE: 61.65 (-1.74)
Spark Therapeutics Announces Multiple Presentations at Upcoming Investor Meetings
GlobeNewswire - Tue May 03, 4:15PM CDT
Spark Therapeutics (NASDAQ:ONCE) today announced that members of its management team will participate in three upcoming conferences in May:
ONCE: 61.65 (-1.74), DB: 13.04 (+0.36)
Spark Therapeutics Announces Multiple Presentations at Upcoming Scientific Meetings
GlobeNewswire - Thu Apr 28, 4:14PM CDT
Spark Therapeutics (NASDAQ:ONCE) today announced that researchers will make multiple presentations related to the company's broad gene therapy development portfolio at upcoming scientific meetings.
ONCE: 61.65 (-1.74)
Spark Therapeutics to Participate in Multiple Upcoming Conferences
GlobeNewswire - Wed Sep 21, 6:30AM CDT
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing potential one-time, life-altering treatments, announced today that members of company management or key investigators will present at the following upcoming conferences:
ONCE: 61.65 (-1.74)
Covered Call reports for Spark Therapeutics, Potash Corporation of Saskatchewan, GNC Holdings, Weight Watchers and Intersil Corporation include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Sep 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GNC, ISIL, ONCE, POT, and WTW.
ONCE: 61.65 (-1.74), GNC: 20.34 (+0.10), POT: 16.34 (+0.25), ISIL: 21.92 (-0.02), WTW: 10.75 (+0.27)
Spark Therapeutics to Participate in Multiple September Conferences
GlobeNewswire - Wed Aug 31, 6:30AM CDT
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments, announced today that members of company management or key investigators will present at the following major investor and scientific/medical conferences in September:
ONCE: 61.65 (-1.74)
Spark Therapeutics Reports Second Quarter 2016 Financial Results and Recent Business Highlights
GlobeNewswire - Wed Aug 10, 6:30AM CDT
Updated timing of the completed BLA submission for voretigene neparvovec
ONCE: 61.65 (-1.74)
Spark Therapeutics Announces New Positive Data from Continuation of Phase 3 Trial of Voretigene Neparvovec
GlobeNewswire - Wed Aug 10, 6:00AM CDT
Of the nine crossover subjects, eight responders demonstrated the maximum improvement measurable on the primary endpoint at one year
ONCE: 61.65 (-1.74)
Drug Stock Earnings to Watch on Aug 10: ONCE, COLL & ARGS
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 8:24AM CDT
The Q2 earning season is drawing to a close as we now have releases from approximately 433 S&P 500 members, accounting for 87.7% of the index's total market capitalization.
ARGS: 4.97 (-0.19), ONCE: 61.65 (-1.74), COLL: 15.70 (+2.88)
Chipotle Mexican Grill, Mercadolibre Incorporated, Spark Therapeutics, Quanta Services Inc., and Nike and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Mon Aug 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CMG, MELI, NKE, ONCE, and PWR.
PWR: 25.91 (+0.20), NKE: 55.36 (+0.02), ONCE: 61.65 (-1.74), CMG: 409.55 (+9.80), MELI: 190.71 (+3.96)
ONCE Crosses Above Average Analyst Target
ETFChannel.com - Tue Aug 02, 8:04AM CDT
In recent trading, shares of Spark Therapeutics Inc have crossed above the average analyst 12-month target price of $58.75, changing hands for $58.87/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to...
ONCE: 61.65 (-1.74)
Spark Therapeutics, Inc. to Host Conference Call on August 10th at 8:30a.m. to Discuss Second Quarter 2016 Results
GlobeNewswire - Tue Aug 02, 6:30AM CDT
Spark Therapeutics (NASDAQ:ONCE) today announced that it will host a conference call on Wednesday, August 10, 2016 at 8:30 a.m. ET to report corporate and financial results for the three and six months ended June 30, 2016.
ONCE: 61.65 (-1.74)
Spark Therapeutics Announces Closing of Public Offering
GlobeNewswire - Mon Jun 20, 3:01PM CDT
Spark Therapeutics, Inc. ("Spark"
(NASDAQ:ONCE) announced today the closing of its previously announced underwritten public offering of common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission, including the exercise in full by the underwriters of their option to purchase an additional 525,000 shares from Spark at the public offering price of $45.00 per share, less the underwriting discount. The exercise of the option brought the total number of shares sold in the offering to 4,025,000, consisting of 3,025,000 shares sold by Spark and 1,000,000 shares sold by The Children's Hospital of Philadelphia Foundation ("CHOP", and increased the aggregate net proceeds to Spark to approximately $128.0 million, after deducting underwriting discounts and before offering expenses. Spark did not receive any proceeds from the sale of shares by CHOP. JPM: 67.32 (+0.48), ONCE: 61.65 (-1.74)
Spark Therapeutics Announces Launch of Public Offering
GlobeNewswire - Mon Jun 13, 3:47PM CDT
Spark Therapeutics, Inc. ("Spark"
(NASDAQ:ONCE) announced today that it has commenced an underwritten public offering of 3,500,000 shares of its common stock pursuant to an automatically effective shelf registration statement that has been filed with the Securities and Exchange Commission. The offering consists of 2,500,000 shares being offered by Spark and 1,000,000 shares being offered by The Children's Hospital of Philadelphia Foundation ("CHOP". In addition, Spark is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 525,000 shares at the public offering price, less the underwriting discount. Spark will not receive any proceeds from the sale of shares by CHOP. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. JPM: 67.32 (+0.48), ONCE: 61.65 (-1.74)
Spark Therapeutics Announces Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity
GlobeNewswire - Mon Jun 13, 6:15AM CDT
All four subjects received one-time administration of SPK-9001 at initial low dose for a cumulative 58-weeks of follow-up without the need for immunosuppression
ONCE: 61.65 (-1.74), PFE: 34.18 (-0.10)
Spark Therapeutics, Inc. to Host Conference Call on Monday June 13th at 8:30 a.m. to Discuss SPK-9001 Phase 1/2 Data for the Treatment of Hemophilia B Presented at EHA
GlobeNewswire - Thu Jun 09, 6:30AM CDT
Spark Therapeutics (NASDAQ:ONCE) announced today that it will host a conference call on Monday, June 13, 2016 at 8:30 a.m. ET to discuss updated results of the first cohort from the ongoing Phase 1/2 clinical trial of SPK-9001, the lead investigational compound in the SPK-FIX program in collaboration with Pfizer, Inc., which is being studied for the treatment of hemophilia B. Spark also will provide an update on preclinical data in its SPK-FVIII program for the treatment of hemophilia A.
ONCE: 61.65 (-1.74)
Spark Therapeutics Announces Participation and Attendance for Conferences in June
GlobeNewswire - Mon Jun 06, 6:30AM CDT
Spark Therapeutics (NASDAQ:ONCE) announced today that members of its management team will participate in and attend the following conferences in June:
ONCE: 61.65 (-1.74)
Pfizer's (PFE) Trumenba Accepted for Review in the EU
Zacks Equity Research - Zacks Investment Research - Mon May 23, 9:33AM CDT
Pfizer (PFE) and Spark Therapeutics (ONCE) announced encouraging new hemophilia B data; Pfizer also announced that Trumenba is under review in the EU.
ANIP: 66.68 (+1.56), ONCE: 61.65 (-1.74), PFE: 34.18 (-0.10), BMY: 56.45 (+0.52)
Spark Therapeutics and Pfizer Announce Data from Initial Subjects in Hemophilia B Trial Demonstrating Consistent Therapeutic Levels of Factor IX Expression
GlobeNewswire - Thu May 19, 5:30AM CDT
Subjects received one-time administration of a highly optimized gene therapy at initial low dose without the need for immunosuppression
ONCE: 61.65 (-1.74), PFE: 34.18 (-0.10)
Spark Therapeutics Reports First Quarter 2016 Financial Results and Recent Business Highlights
GlobeNewswire - Wed May 04, 6:29AM CDT
Company makes progress across multiple programs
ONCE: 61.65 (-1.74)
Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Pipeline Review 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Biovista, Khondrion, Spark Therapeutics - Research and Markets
BusinessWire - Wed May 04, 2:50AM CDT
Research and Markets has announced the addition of the "Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H1 2016" drug pipelines to their offering.
ONCE: 61.65 (-1.74)
Spark Therapeutics Announces Multiple Presentations at Upcoming Investor Meetings
GlobeNewswire - Tue May 03, 4:15PM CDT
Spark Therapeutics (NASDAQ:ONCE) today announced that members of its management team will participate in three upcoming conferences in May:
ONCE: 61.65 (-1.74), DB: 13.04 (+0.36)
Spark Therapeutics Announces Multiple Presentations at Upcoming Scientific Meetings
GlobeNewswire - Thu Apr 28, 4:14PM CDT
Spark Therapeutics (NASDAQ:ONCE) today announced that researchers will make multiple presentations related to the company's broad gene therapy development portfolio at upcoming scientific meetings.
ONCE: 61.65 (-1.74)
(0)
(0)Scroll down for more posts ▼